Nanobacteria: Fact or fiction? Characteristics, detection, and medical importance of novel self-replicating, calcifying nanoparticles

Journal of Investigative Medicine

Volumn 54, Issue 7, 2006, Pages 385-394

  Ciftcioglu, Neva ^a   McKay, David S ^a   Mathew, Grace ^a   Kajander, E Olavi ^b  

^a NASA JOHNSON SPACE CENTER   (United States)

^b Nanobac Life Sciences   (Finland)

Author keywords

Biomineralization; Calcification; Nanobacteria; Nanoparticles

Indexed keywords

NANOPARTICLE;

BIOMINERALIZATION; CALCIFICATION; CONFERENCE PAPER; CRYSTALLIZATION; KIDNEY CALCIFICATION; MICROORGANISM; NANOBACTERIA; PARTICLE SIZE;

EID: 33846291359     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2006.06018     Document Type: Conference Paper

References (79)

1. Sarikaya M. Biomimetics: materials fabrication through biology. PNAS 1999;96:14183-5.
2. Tadic D, Peters F, Epple M. Continuous synthesis of amorphous carbonated apatites. Biomaterials 2002;23:2553-9.
3. Inayat-Hussam SH, Rajab NF, Roslie H, et al. Cell death induced by hydroxyapatite on L929 fibroblast cells. Med J Malaysia 2004;59:176-7.
4. Barroug A, Kuhn LT, Gerstenfeld LC, Glimcher MJ. Interactions of cisplatin with calcium phosphate nanoparticles: in vitro controlled adsorption and release. J Orthop Res 2004;22:703-8.
5. Rauschmann MA, Wichelhaus TA, Stirnal V, et al. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections. Biomaterials 2005;26:2677-84.
6. Tamai N, Myoui A, Tomita T et al. Novel hydroxyapatite ceramics with an interconnective porous structure exhibit superior osteoconduction in vivo. J Biomed Mater Res 2002;59:110-17.
7. Albiar E, Holds JB. Hydroxyapatite orbital implants: indications for use and nursing considerations. J Ophthalmic Nurs Technol 1992;11:71-6.
8. Mizushima Y, Ikoma T, Tanaka J, et al. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. J Control Release 2006;110:260-5.
9. Guo D, Xu K, Zhao X, et al. Development of a strontium-containing hydroxyapatite bone cement. Biomaterials 2005;26:4073-83.
10. Giachelli CM. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res 2005;8:229-31.
11. Parhami F, Bostrom K, Watson K, et al. Role of molecular regulation in vascular calcification. J Atherioscler Thromb 1996;3:90-4.
12. Schoenhagen P, Tuzcu EM. Coronary artery calcification and end-stage renal disease: vascular biology and clinical implications. Cleve Clin J Med 2002;69:12-20.
13. Demer LL. A skeleton in the atherosclerosis closet. Circulation 1995;92:2029-32.
14. Wexler L, Brundage B, Grouse J, et al. Coronary artery calcification; pathophysiology, epidemiology, imaging methods, and clinical implications. Circulation 1996;94:1175-92.
15. Jono S, Shioi A, Ikari Y, et al. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006;24:176-81.
16. Blair B, Fabrizio M. Pharmacology for renal calculi. Exp Opin Pharmacother 2000;3:435-41.
17. Sohshang HL, Singh MA, Singh NG, et al. Biochemical and bacteriological study of urinary calculi. J Commun Dis 2000;32:216-21.
18. Driessens FC, Verbeeck RM, van Dijk JW. Plasma calcium difference between man and vertebrates. Comp Biochem Physiol A 1989;93:651-4.
19. Kajander EO, Ciftcioglu N. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci U S A 1998;95:8274-9.
20. Miller VM, Rodgers G, Charlesworth JA, et al. Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. Am J Physiol Heart Circ Physiol 2004;287:1115-24.
21. Puskas LG, Tiszlavicz L, Razga Z, et al. Detection of nanobacteria-like particles in human atherosclerotic plaques. Acta Biol Hung 2005;56:233-45.
22. Ciftcioglu N, McKay DS, Kajander EO. Nanobacteria might be one of the potential agents in oral flora triggering peripheral arterial diseases. Circulation 2003;108:58-9.
23. Kajander EO, Liesi P, Ciftcioglu N. Do autonomously replicating sterile-filterable particles have an association with amyloid accumulation? Viruses and virus-like agents in disease [abstract]. In: 2nd Karger Symposium, Basel, Switzerland. 1993. p. 41.
24. Ciftcioglu N, Björklund M, Willman K, et al. Nanobacteria: an infectious cause for kidney stone formation. Kidney Int 1999;56:1893-8.
25. Ciftcioglu N, Haddad RS, Golden DC, et al. A potential cause for kidney stone formation during space flights: enhanced growth of nanobacteria in microgravity. Kidney Int 2005;67:483-91.
26. Ciftcioglu N. Kidney stone formation: an infectious disease? Jpn J Urol Sur 2002;15:228-32.
27. Kajander EO, Ciftcioglu N, Aho K, et al. Characteristics of nanobacteria and their possible role in stone formation. Urol Res 2003;31:47-54.
28. Shiekh FA, Khullar M, Singh SK. Lithogenesis: induction of renal calcifications by nanobacteria. Urol Res 2006;20:1-5.
29. Hjelle JT, Miller-Hjelle MA, Poxton IR, et al. Endotoxin and nanobacteria in polycystic kidney disease. Kidney Int 2000;57:2360-74.
30. Kajander EO, Ciftcioglu N, Miller-Hjelle MA, et al. Nanobacteria: controversial pathogens in nephrolithiasis and polycystic kidney disease. Curr Opin Nephrol Hypertens 2001;10:445-52.
31. Wen Y, Li YG, Yang ZL, et al. Detection of nanobacteria in serum, bile and gallbladder mucosa of patients with cholecystolithiasis. Chin Med J 2005;118:421-4.
32. Wood HM, Shoskes DA. The role of nanobacteria in urologic disease. World J Urol 2006;24:51-4.
33. Shoskes DA, Thomas KD, Gomez E. Anti-nanobacterial therapy for men with chronic prostatitis/chronic pelvic pain syndrome and prostatic stones: preliminary experience. J Urol 2005;173:474-7.
34. Jelic TM, Malas AM, Groves SS, et al. Nanobacteria-caused mitral valve calciphylaxis in a man with diabetic renal failure. South Med J 2004;97:194-8.
35. Lopez-Brea M, Selgas R. Nanobacteria as a cause of renal diseases and vascular calcifying pathology in renal patients ("endovascular lithiasis"). Enferm Infecc Microbiol Clin 2000;18:491-2.
36. Hudelist G, Singer CF, Kubista E, et al. Presence of nanobacteria in psammoma bodies of ovarian cancer: evidence for pathogenetic role in intratumoral biomineralization. Histopathology 2004;45:633-7.
37. Wainwright M. Nanobacteria and associated 'elementary bodies' in human disease and cancer. Microbiology 1999;145:2623-4.
38. Ciftcioglu N, Björklund M, Kajander EO. Stone formation and calcification by nanobacteria in human body. Proc SPIE 1998;3441:105-11.
39. Miller-Hjelle MA, Hjelle JT, Ciftcioglu N, et al. Nanobacteria: methods for growth and identification of this recently discovered calciferous agent. In: Olson WP, editor. Rapid analytical microbiology, The chemistry and physics of microbial identification. Surrey (UK): Davis Horwood International Publishing; 2003. p. 297-312.
40. Kajander EO, Kuronen I, Åkerman K, et al. Nanobacteria from blood, the smallest culturable autonomously replicating agent on earth. Proc SPIE 1997;3111:420-8.
41. Ciftcioglu N, Miller-Hjelle MA, Hjelle JT, et al. Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method. Antimicrob Agents Chemother 2002;46:2077-86.
42. Evan AP, Bledsoe SB, Connors BA, et al. Sequential analysis of kidney stone formation in the Aprt knockout mouse. Kidney Int 2001;60:910-23.
43. Naito Y, Ohtawara Y, Kageyama S, et al. Morphological analysis of renal cell culture models of calcium phosphate stone formation. Urol Res 1997;25:59-65.
44. Riccio V, Della Ragione F, Marrone G, et al. Cultures of human embryonic osteoblasts. A new in vitro model for biocompatibility studies. Clin Orthop Relat Res 1994;308:73-8.
45. Vali H, McKee MD, Ciftcioglu N, et al. Nanoforms: a new type of protein-associated mineralization. Geoch Cosmoch Acta 2001;65:63-74.
46. Becker W, Marxen J, Epple M, et al. Influence of microgravity on crystal formation in biomineralization. J Appl Physiol 2000;89:1601-7.
47. Whitson PA, Pietrzyk RA, Sams CF. Urine volume and its effects on renal stone risk in astronauts. Aviat Space Environ Med 2001;72:368-72.
48. Pak CY, Hill K, Cintron NM, et al. Assessing applicants to the NASA flight program for their renal stone-forming potential. Aviat Space Environ Med 1989;60:157-61.
49. McCarthy ID. Fluid shifts due to microgravity and their effects on bone: a review of current knowledge. Ann Biomed Eng 2005;33:95-103.
50. Maniloff J. Nannobacteria: size limits and evidence. Science 1996;273:924-30.
51. Glass JI, Assad-Garcia N, Alperovich N, et al. Essential genes of a minimal bacterium. Proc Natl Acad Sci USA 2006;103:425-30.
52. Cisar JO, Xu DQ, Thompson J, et al. An alternative interpretation of nanobacteria-induced biomineralization. Proc Natl Acad Sci U S A 2000;97:11511-5.
53. Ciftcioglu N, Kajander EO. Interaction of nanobacteria with cultured mammalian cells. Pathophysiology 1998;4:259-70.
54. Kajander EO. Calcific nano-particles; nature's "nanotechnology" as a cause of human disease [abstract]. In: Nanotox 2006, January 29th-February 1st, Miami, FL.
55. Åkerman KK, Kuikka JT, Ciftcioglu N, et al. Radiolabeling and in vivo distribution of nanobacteria in rabbit. Proc SPIE 1997;3111:436-42.
56. Aho KM, Kajander EO, Ciftcioglu N. A novel multiplex-like ELISA test reveals that both Gla-clotting and anticalcification proteins are present on calcifying nano-particles [abstract]. The ASCB 45th Annual Meeting, December 10-14, 2005, San Francisco.
57. Wahl C, Hess B. Kidney calculi-is nutrition a trigger or treatment? Ther Umsch 2000;57:138-45.
58. Trinchieri A, Castelnuovo C, Lizzano R, et al. Calcium stone disease: a multiform reality. Urol Res 2005;33:194-8.
59. Evan AP, Coe FL, Lingeman JE, et al. Insights on the pathology of kidney stone formation. Urol Res 2005;33:383-9.
60. Evan AP, Coe FL, Rittling SR, et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 2005;68:145-54.
61. Khullar M, Shanna SK, Singh SK, et al. Morphological and immunological characteristics of nanobacteria from human renal stones of a north Indian population. Urol Res 2004;32:190-5.
62. Drancourt M, Jacomo V, Lepidi H, et al. Attempted isolation of Nanobacterium sp. microorganisms from upper urinary tract stones. J Clin Microbiol 2003;41:368-72.
63. Burton EM, Hanna JD, Mercado-Deane MG. Nephrocalcinosis in a child with autosomal dominant polycystic kidney disease and a prolapsing ectopic ureterocele. Pediatr Radiol 1995;25:462-5.
64. Anim JT, Kehinde EO, Prasad A, et al. Relationship between serum prostate specific antigen and the pattern of inflammation in both benign and malignant prostatic disease in Middle Eastern men. Int Urol Nephrol 2006;38:27-32.
65. Muezzinoglu B, Gurbuz Y. Stromal microcalcification in prostate. Malays J Pathol 2001;23:31-3.
66. Geramoutsos I, Gyftopoulos K, Perimenis P, et al. Clinical correlation of prostatic lithiasis with chronic pelvic pain syndromes in young adults. Eur Urol 2004;45:333-7.
67. Torres Ramirez C, Aguilar Ruiz J, Zuluaga Gomez A, et al. Ultrastructure of primary or endogenous prostatic calculi. Scanning electron microscopic study. Arch Esp Urol 1981;34:13-22.
68. Maniscalco BS, Taylor KA. Calcification in coronary artery disease can be reversed by EDTA-tetracycline long-term chemotherapy. Pathophysiology 2004;11:95-101.
69. Zhu J, Kajander EO, Katz RJ, et al. Increased serum levels of nanobacteria antibodies are associated with high coronary calcification score. Supp Circ 2004;110:627.
70. Ertas F, Hasan T, Akan O, et al. Anti-nanobacterial antibody titer is an independent risk factor for coronary artery calcification [abstract]. American College of Cardiology 55th Annual Scientific Session Exposition. March 11-14, Atlanta.
71. Sedivy R, Battistutti WB. Nanobacteria promote crystallization of psammoma bodies in ovarian cancer. APMIS 2003;111:951-4.
72. Sommer AP, Pavlath AE. Primordial proteins and HIV. J Proteome Res 2005;4:633-6.
73. Pretonus AM, Sommer AP, Aho KM, et al. HIV and nanobacteria. HIV Med 2004;5:391-3.
74. Ciftcioglu N, Ciftcioglu V, Vali H, et al. Sedimentary rocks in our mouth: dental pulp stones made by nanobacteria. Proc SPIE 1998;3441:130-5.
75. Sommer AP. Could reduced bone mineral densities in HIV be caused by nanobacteria? J Proteome Res 2004;3:670-2.
76. García-Cuerpo E, Kajander EO, Ciftcioglu N, et al. Nanobacteria: un modelo de neo-litogenesis experimental. Arch Esp Urol 2000;53:291-303.
77. Zhou HD, Li GY, Yang YX, et al. Intracellular co-localization of SPLUNC1 protein with nanobacteria in nasopharyngeal carcinoma epithelia HNE1 cells depended on the bactericidal permeability increasing protein domain. Mol Immunol 2006;43(11):1864-71.
78. Ciftcioglu N, Kuronen I, Åkerman K, et al. A new potential threat in antigen and antibody products: nanobacteria. In: Brown F, Burton D, Doherty P, et al, editors. Vaccines 97. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. p. 99-103.
79. Kajander EO, Aho K, Ciftcioglu N. Detection of nanobacteria in viral vaccines. 101th General Meeting of American Society for Microbiology in May 20-24, 2001 in Orlando, USA. Paper Y-3.